| 先端癌治療特集 |
 |
用途別にデータベース、調査資料等をご紹介いたします |
BioSeeker Group社
発行 |
|
|
|
【 英文市場調査報告書 】
血液産業
The Blood Industry
|
|
|
|
|
 |
 |
※この商品は英文にてご提供いたします。 |
Abstract
INTRODUCTION
The goal of this study on the blood industry is to describe and analyze the
current markets for blood products, blood tests, and blood processing
equipment as well as present important new developments affecting every aspect
of this industry. In addition, the report provides an analysis of market value
forecasted through 2012 in constant dollars and participating company
profiles. The study covers the major aspects of blood and plasma
collection/transfusion, including autologous donations, apheresis,
fractionation, blood salvage, and stem cells. The major plasma products such
as coagulation factors, human serum albumin, and immunoglobulins are analyzed
as well. The scope and character of the blood testing segment is constantly
changing so the impact of new products, technologies, and equipment are
analyzed.
The study also covers federal regulation of the blood supply, blood system
management, an analysis of the companies serving these markets, the
international developments in blood banking, and related areas as well as
research and patents that will affect the future of the blood industry.
SCOPE OF STUDY
This report contains:
- Descriptions of various types of blood and plasma collection and
transfusion technologies including autologous donations, apheresis,
fractionation, blood salvage and stem cells, and major plasma products such as
coagulation factors, human serum albumin
- The current U.S. blood industry market status, with trends and forecasts
for growth over the next 5 years
- Technological issues including the latest trends and a thorough patent
analysis
- Analysis of federal regulations concerning blood supply and management
- Discussion of the international markets for various blood and
blood-related products.
METHODOLOGY AND INFORMATION SOURCES
Data for this study were collected using both primary and secondary data
research techniques. A literature search of BCC' s extensive library as well as
scientific, medical, and business libraries was conducted. On-line databases
and government sources were consulted as well. Extensive interviews with
industry personnel, scientists, professional and trade organizations,
government agency personnel, observers, scientists, and industry professionals
were conducted.
ANALYST CREDENTIALS
Mary Anne Crandall is an expert industry analyst who has specialized in the
pharmaceutical industry for the past 15 years. She has completed several
in-depth studies on various medical topics, which has required both medical
expertise and excellent knowledge of the pharmaceutical industry. Crandall has
a master' s degree in psychology, a PhD in natural health, and is a registered
nurse (RN)/instructor at Southern Oregon University (Ashland, OR).
Table of Contents
- The Blood Industry
- Chapter 1 - SUMMARY
- SUMMARY TABLE: U.S. BLOOD MARKET, THROUGH 2012 ($ MILLIONS)
- SUMMARY FIGURE: U.S. BLOOD MARKET, 2007 AND 2012 ($ MILLIONS)
- Chapter 2 - OVERVIEW
- THE BLOOD INDUSTRY
- MARKET STRUCTURE AND SIZE
- TABLE 1 U.S. BLOOD PRODUCTS AND COLLECTION AND PROCESSING PRODUCTS MARKET,
THROUGH 2012 ($ MILLIONS)
- HISTORY OF THE BLOOD INDUSTRY
- TABLE 2 TIMELINE OF THE BLOOD INDUSTRY
- TABLE 2 (CONTINUED)
- TABLE 3 COMPOSITION OF BLOOD
- CELLULAR ELEMENTS
- Red and White Blood Cells
- Platelets
- IMMUNOGLOBULIN PRODUCTS
- THE DANGERS OF TRANSFUSED BLOOD
- TRANSFUSION ASSOCIATED RISKS
- Diseases Contracted from Blood Transfusions and Related Identification
Testing
- TABLE 4 MAJOR DISEASES CONTRACTED FROM BLOOD TRANSFUSIONS
- TABLE 4 (CONTINUED)
- TABLE 5 CBER-LICENSED HIV DONOR SCREENING TESTS
- TABLE 5 (CONTINUED)
- TABLE 6 CBER-LICENSED SCREENING TESTS FOR HEPATITIS B
- TABLE 7 CBER-LICENSED SCREENING TESTS FOR HEPATITIS C
- Hepatitis D
- Hepatitis E
- Human T Cell Lymphotropic Virus-(HTLV-I, -II)
- TABLE 8 CBER-LICENSED SCREENING TESTS FOR HTLV-I AND HTLV-II
- TABLE 9 CBER-LICENSED SCREENING TESTS FOR CMV
- TABLE 9 (CONTINUED)
- TABLE 10 CBER-LICENSED SCREENING TESTS FOR WEST NILE
- "Mad Cow Disease"-Creutzfeldt-Jakob Disease (CJD)
- Syphilis
- Chagas Disease
- Chagas Disease (Continued)
- Current Status of Blood Donor Screening for Chagas Disease
- EFFORTS TO CREATE A VIRUS-FREE BLOOD SUPPLY
- Plasma Treatments
- Trinitrobutyl Phosphate and Sodium Cholate
- Methylene Blue-treated Plasma
- Amatosalen HCL-Treated Plasma
- Platelet Treatments
- RBCs
- NEGATIVE REACTIONS FROM BLOOD TRANSFUSIONS
- Negative Reactions from Blood ý (Continued)
- BLOOD/PLASMA COMPONENT RISKS
- Chapter 3 - THE BLOOD MANAGEMENT SYSTEM: BLOOD COLLECTION, PROCESSING, AND
USE
- BLOOD COLLECTION
- ORGANIZATIONS COLLECTING BLOOD
- For-profit Blood Collection
- Plasma Collection Centers
- National Donor Deferral Registry
- Nonprofit Blood Collection
- American Red Cross
- Community Blood Banks
- Hospitals
- Other Blood Collection Sites
- BLOOD DONATION DEMOGRAPHICS
- DONOR RECRUITMENT AND REGULATIONS
- BLOOD SCREENING AND EVALUATION
- METHODS FOR COLLECTING BLOOD FROM A DONOR
- Manual Collection
- Automated Collection
- Plasmapheresis
- Plateletpheresis
- Leukopheresis
- Red Blood Cell Apheresis
- PLASMA COLLECTION
- Commercial Nature of Plasmapheresis
- Global Nature of the Plasma Industry
- Plasma Fractionators
- Distributors/Brokers
- BLOOD TYPING AND TESTING FOR DISEASES
- TABLE 11 TESTS ROUTINELY PERFORMED ON BLOOD DONATIONS
- TABLE 11 (CONTINUED)
- TABLE 12 BLOOD TYPE ANTIGEN/ANTIBODY REACTIONS
- Methods of Typing
- Manual Blood Typing Methods
- Slide/Tile Testing
- Tube Testing
- Microplate
- Automated Blood Typing and Screening Methods
- Blood Testing
- BLOOD PROCESSING
- Preparation and Use of the Components
- Red Blood Cell Components
- Platelets
- BLOOD TRANSFUSIONS
- Testing before Transfusion
- Manual Crossmatch Techniques
- Major Crossmatch
- Minor Crossmatch
- Antibody Screen
- Coombs Test
- TYPES OF TRANSFUSIONS
- Whole Blood
- Packed Red Blood Cells
- Platelets
- Leukocytes
- Fresh Frozen Plasma (FFP)
- TABLE 13 SELECTED USES OF FFP
- Cryoprecipitate
- Coagulation Factors
- TABLE 14 LISTING OF BLOOD PRODUCTS FOR THERAPEUTIC USE
- Immune Serum Globulin/Intramuscular Immune Globulins
(IMIG)/Intravenous Immune Globulin (IGIV)
- Factor VIII
- Factor IX and Factor IX Complex
- Factor VIIa
- Fibrin/Thrombin
- Therapeutic Apheresis
- BLOOD MANAGEMENT ISSUES
- AVAILABILITY ISSUES
- BLOODLESS SURGERY
- SAFETY ISSUES-RISK MANAGEMENT
- TABLE 15 FACTORS TO REDUCE RISKS OF TRANSFUSION-ASSOCIATED DISEASES
- Better Donor Screening
- Better Viral Screening Tests
- Get More Repeat Donors
- Develop Better Viral Inactivation Processes
- Selective Use of Blood Derivative Products
- Chapter 4 - REGULATION OF THE BLOOD BUSINESS
- REGULATION OF THE U.S. BLOOD BUSINESS
- TABLE 16 FEDERAL ORGANIZATIONS RESPONSIBLE FOR U.S. BLOOD SAFETY
- TABLE 16 (CONTINUED)
- STATUTORY AUTHORITY OF THE FDA
- Center for Biologics Evaluation and Research
- Office of Regulatory Affairs (ORA)
- Office of Biologics, the Division of Blood and Blood Products
- TABLE 17FDA AUTHORITY IN REGULATING BLOOD BANKING AND BLOOD PRODUCTS
- THE MAJOR REGULATIONS AND POLICY MATTERS CONCERNING THE U.S.BLOOD
SUPPLY
- The Clinical Laboratory Improvement Act of 1988 (CLIA)
- The FDA' S Five Layers
- The FDA Blood Action Plan
- TABLE 18 MAIN BLOOD REGULATION ISSUES IDENTIFIED BY THE FDA
- TABLE 18 (CONTINUED)
- HOW REGULATIONS GET IMPLEMENTED
- Inspecting Blood Banks and Plasma Collection Facilities
- TABLE 1914 MAJOR AREAS OF CONCERN FOR INSPECTING BLOOD FACILITIES
- OTHER ORGANIZATIONS INVOLVED IN BLOOD REGULATION
- National Heart, Lung, and Blood Institute (NHLBI)
- Blood Diseases and Resources Program
- Occupational Safety and Health Administration (OSHA)
- Health Care Financing Administration (HCFA)
- The Department of Defense
- State Regulatory Agencies
- VOLUNTARY REGULATION BY PROFESSIONAL AND TRADE ASSOCIATIONS
- American Association of Blood Banks
- American Blood Resources Association
- America' s Blood Centers (ABC)
- PPTA: Plasma Products Therapeutics Association
- THE EUROPEAN UNION (EU) BLOOD DIRECTIVE
- International Society for Blood Transfusion (ISBT) 128
- THE FUTURE OF BLOOD REGULATION
- Chapter 5 - THE BLOOD AND BLOOD PRODUCTS MARKET
- DRIVING FORCES OF THE INDUSTRY
- FIGURE 1 VARIABLES INFLUENCING THE DYNAMICS OF DEMAND FOR BLOOD FOR
TRANSFUSION
- MARKET OVERVIEW
- FIGURE 2 BLOOD MARKET COST AND PRICING ANALYSIS
- TABLE 20 U.S. BLOOD COLLECTION AND TRANSFUSION DATA, THROUGH 2012
(MILLION UNITS/PTS.)
- FIGURE 3 U.S. BLOOD COLLECTION AND TRANSFUSION DATA, 2005-2012 (MILLION
UNITS/PTS.)
- TABLE 21 U.S. PLASMA COLLECTION DATA, THROUGH 2012 (MILLION UNITS/L)
- FIGURE 4 U.S. PLASMA COLLECTION DATA, 2005-2012 (MILLION UNITS/L)
- CHANGING PATTERNS OF TRANSFUSION PROCEDURES
- Leukoreduction
- Impact of Autologous Donations
- Types of Autologous Transfusions
- Risks of PABD
- PRICING OF BLOOD
- TABLE 22 COST OF BLOOD COMPONENTS, THROUGH 2012 ($)
- National Blood Exchange (NBE)
- RBCs and Leukoreduced RBCs
- Platelets
- Random Donor Platelets
- Fresh Frozen Plasma (FFP)
- Cryoprecipitate
- Washed Cells
- Deglycerolized Cells
- Other Blood Components
- Granulocytes
- Gamma-Irradiated Blood
- AVERAGE COST OF TRANSFUSION
- TABLE 23 AVERAGE COST OF TRANSFUSION TO PATIENT BY PRODUCT TYPE, 2007 ($)
- PLASMA AND PLASMA-DERIVED PRODUCTS
- Plasma Market Size
- Plasma Therapeutic Products
- TABLE 24 U.S. MARKET SIZE PLASMA THERAPEUTIC DERIVATIVES BY TYPE,
THROUGH 2012 ($ MILLIONS)
- FIGURE 5 SHARE OF PLASMA THERAPEUTIC DERIVATIVES BY TYPE, 2007 AND 2012
(%)
- Albumin and Plasma Protein Fraction (PPF)
- FDA Notification Regarding Safety of Albumin Administration in
Critically Ill
- Recombinant Human Albumin
- Albumin Market Dynamics
- TABLE 25 CURRENTLY MARKETED ALBUMIN AND PLASMA PROTEIN FRACTION (PPF)
PRODUCTS
- Albumin and PPF Market Size
- TABLE 26 U.S. MARKET FOR HUMAN SERUM ALBUMIN AND PPF, THROUGH 2012
(UNITS, PRICE, AND VALUE)
- TABLE 27 BLOOD CLOTTING FACTORS
- TABLE 28 WORLDWIDE AND U.S.HEMOPHILIA STATISTICS, 2007
- Market Demand and Market Size
- TABLE 29 U.S. MARKET FOR PLASMA-DERIVED AND RECOMBINANT CLOTTING
FACTORS, THROUGH 2012 ($ MILLIONS)
- FIGURE 6 U.S. SHARE FOR PLASMA-DERIVED AND RECOMBINANT CLOTTING FACTORS,
2007 AND 2012 (%)
- TABLE 30 FDA-APPROVED FACTOR VIII PRODUCTS
- TABLE 30 (CONTINUED)
- TABLE 31 U.S. MARKET SHARE FACTOR VIII COMPANIES, 2007
- FIGURE 7 MARKET SHARE OF FACTOR VIII COMPANIES, 2007 (%)
- TABLE 32 FDA-APPROVED FACTOR IX PRODUCTS
- Factor VIIa
- Other Factors
- Prothrombin Complex Concentrates
- TABLE 33 FDA-APPROVED PROTHROMBIN COMPLEX CONCENTRATE PRODUCTS
- Fibrin Sealants and Thrombin
- TABLE 34 U.S. MARKET FOR FIBRIN/THROMBIN, THROUGH 2012 ($ MILLIONS)
- TABLE 35 U.S. MARKET FOR ANTITHROMBIN III-THROMBATE, THROUGH 2012 ($
MILLIONS)
- TABLE 36 SELECTED CONDITIONS TREATED BY IVIG
- TABLE 37 FDA-APPROVED IMMUNOGLOBULINS
- TABLE 38 FDA-APPROVED HYPERIMMUNE IMMUNOGLOBULINS
- TABLE 38 (CONTINUED)
- Immunoglobulin Market Size
- TABLE 39 U.S. MARKET FOR IMMUNOGLOBULINS BY TYPE, THROUGH 2012 ($
MILLIONS)
- FIGURE 8 U.S. MARKET FOR IMMUNOGLOBULINS BY TYPE, 2007 AND 2012 ($
MILLIONS)
- RSV
- CMV Immunoglobulin
- Hepatitis B Immune Globulin
- RhoD Immunoglobulin
- Tetanus Immunoglobulin (TIG)
- Rabies Immunoglobulin
- Varicella Immunoglobulin
- Vaccinia Immune Globulin Intravenous (VIG)
- Alpha-1-Proteinase Inhibitor
- Alpha-1-Proteinase (Continued)
- Chapter 6 - BLOOD TESTING AND TYPING MARKETS
- MARKET SIZE
- TABLE 40 VALUE U.S. BLOOD TYPING AND BLOOD SCREENING MARKET, THROUGH
2012 ($ MILLIONS)
- FIGURE 9 VALUE AND MARKET SHARE OF U.S. BLOOD TYPING AND BLOOD SCREENING
MARKET, 2007 AND 2012 (%)
- TYPES OF TESTING
- POLYMERASE CHAIN REACTION (PCR) AMPLIFICATION
- TABLE 41 CBER-LICENSED PCR SCREENING TESTS
- TABLE 41 (CONTINUED)
- NUCLEIC ACID AMPLIFICATION TEST (NAT)
- TABLE 42 CBER-LICENSED NAT DONOR SCREENING TESTS
- IMMUNOASSAY
- TABLE 43 IMMUNOASSAY CBER-LICENSED SCREENING TESTS
- TABLE 43 (CONTINUED)
- MARKET SIZE BLOOD TESTING PRODUCTS FOR DONOR SCREENING
- TABLE 44 AVERAGE COST OF DONOR BLOOD TESTING, 2007 AND 2012 ($ MILLIONS)
- TABLE 45 THE U.S. BLOOD DONOR SCREENING TESTING MARKET BY TYPE OF TESTS,
THROUGH 2012 ($ MILLIONS)
- FIGURE 10 U.S. BLOOD DONOR SCREENING TESTING MARKET BY TYPE, 2007 AND
2012 ($ MILLIONS)
- MARKET PARTICIPANTS DONOR SCREENING PRODUCTS
- TABLE 46 LIST OF SUPPLIERS DONOR SCREENING TESTS
- TABLE 47 THE U.S. BLOOD TYPING MARKET-INSTRUMENTS AND SUPPLIES BY TYPE,
THROUGH 2012 ($ MILLIONS)
- MARKET STRUCTURE AND PARTICIPANTS
- Manual Typing Methods
- Automated Blood Typing
- Immucor
- Ortho
- Olympus
- BLOOD COLLECTION/TRANSFUSION PRODUCTS AND PROCESSING EQUIPMENT AND
SUPPLIES
- TABLE 48 U.S. MARKET FOR BLOOD AND PLASMA COLLECTION/TRANSFUSION
PRODUCTS, THROUGH 2012 ($ MILLIONS)
- TABLE 49 U.S. MARKET FOR COLLECTION PRODUCTS BY TYPE, THROUGH 2012 ($
MILLIONS)
- PLASMA AND BLOOD COLLECTION EQUIPMENT
- TABLE 50 U.S. MARKET FOR BLOOD AND PLASMA COLLECTION EQUIPMENT BY TYPE,
THROUGH 2012 ($ MILLIONS)
- FIGURE 11 SHARE OF U.S. MARKET FOR BLOOD AND PLASMA COLLECTION PRODUCTS
BY TYPE, 2007 AND 2012 (%)
- Blood Salvage
- OTHER COLLECTION EQUIPMENT
- TABLE 51 U.S. MARKET FOR OTHER PLASMA COLLECTION PRODUCTS, THROUGH 2012
($ MILLIONS)
- MARKET PARTICIPANTS
- Haemonetics
- PCS2
- TCD Total Containment Unit
- MCS+ 8150 System
- Cell Saver System
- OrthoPAT System
- ACP 215 System
- Baxter
- Autopheresis-C
- Alyx Component Collection System
- CS-3000 Plus Blood Cell Separator
- Amicus Separator
- Gambro BCT
- PLASMA COLLECTION SETS
- TABLE 52 U.S. MARKET FOR PLASMA COLLECTION SETS, THROUGH 2012 ($
MILLIONS)
- TABLE 53 U.S. MARKET FOR BLOOD BAGS, THROUGH 2012 ($ MILLIONS)
- TABLE 54 U.S. MARKET FOR TRANSFUSION PRODUCTS BY TYPE, THROUGH 2012 ($
MILLIONS)
- TABLE 55 U.S. MARKET FOR TRANSFUSION SETS, THROUGH 2012 ($ MILLIONS)
- TABLE 56 U.S. MARKET FOR FILTERS, THROUGH 2012 ($ MILLIONS)
- TABLE 57 U.S. MARKET FOR TRANSFUSION ACCESSORIES, THROUGH 2012 ($
MILLIONS)
- Chapter 7 - TECHNOLOGY
- CLASSICAL FRACTIONATION METHODS
- ADVANCED FRACTIONATION METHODS
- AMPLIFICATION METHODS
- POLYMERASE CHAIN REACTION (PCR)
- NUCLEIC AMPLIFICATION TECHNOLOGY (NAT)
- IMMUNOASSAY
- FIGURE 12 THE BASIC ENZYME IMMUNOASSAY (EIA) PROCESS
- Alternate EIA Methods
- Second Antibody Precipitation Method
- Double Antibody Sandwich Method
- Reverse Sandwich Method
- Reverse Sandwich Inhibition Method
- Reverse Sandwich ý (Continued)
- Chapter 8 - BLOOD INDUSTRY: INTERNATIONAL ANALYSIS
- GLOBAL MARKETS FOR WHOLE BLOOD COLLECTIONS
- LOCAL EFFORTS AND IMPROVEMENTS
- South America
- Asia
- Cuba
- India
- Pacific Region
- Africa
- South Africa
- Canada
- Europe
- Austria
- Britain
- France
- Germany
- Italy
- Switzerland
- Turkey
- Russia
- GLOBAL MARKETS FOR SOURCE PLASMA COLLECTIONS
- TABLE 58 PROJECTED GLOBAL (U.S. AND OTHER MARKETS) PLASMA COLLECTIONS,
THROUGH 2012 ($ BILLIONS, MILLIONS LITERS)
- GLOBAL MARKETS FOR BLOOD THERAPEUTICS
- TABLE 59 PROJECTED WORLD (U.S. AND OTHER MARKETS) SALES OF PLASMA
PRODUCTS*, THROUGH 2012 ($ BILLIONS)
- GLOBAL MARKETS FOR BLOOD TYPING AND SCREENING PRODUCTS
- TABLE 60 PROJECTED GLOBAL (U.S. AND OTHER) MARKETS FOR BLOOD TYPING AND
SCREENING PRODUCTS, THROUGH 2012($ MILLIONS)
- GLOBAL MARKETS FOR BLOOD PROCESSING EQUIPMENT AND ASSOCIATED PRODUCTS
- TABLE 61 PROJECTED WORLD SALES OF BLOOD COLLECTION AND PROCESSING
EQUIPMENT AND CONSUMABLES, THROUGH 2012 ($ MILLIONS)
- Chapter 9 - BLOOD RESEARCH AND DEVELOPMENT
- DEDICATED BLOOD RESEARCH FACILITIES
- JEROME H. HOLLAND LABORATORY (ARC)
- NATIONAL BLOOD FOUNDATION (NBF)
- CENTER FOR BLOOD RESEARCH (CBR)
- Center for Blood Research (CBR)ý(Continued)
- Center for Blood Research (CBR)ý(Continued)
- Center for Blood Research (CBR)ý(Continued)
- TABLE 62 SELECTED ADVANCES IN ADULT STEM CELL THERAPIES
- TABLE 62 (CONTINUED)
- BLOOD SUBSTITUTES
- BLOOD SUBSTITUTES (CONTINUED)
- FIBRIN SEALANT
- THE VETERINARY BLOOD MARKET
- TABLE 63 REGIONAL VETERINARY BLOOD BANKS
- THE VETERINARY BLOOD MARKET (CONTINUED)
- Chapter 10 - COMPANY PROFILES
- ABBOTT LABORATORIES
- AMERICA' S BLOOD CENTERS
- AMERICAN ASSOCIATION OF BLOOD BANKS (AABB)
- AMERICAN RED CROSS (ARC)
- BAXTER INTERNATIONAL, INC.
- BIO-RAD LABORATORIES
- CSL BEHRING
- GRIFOLS BIOLOGICALS, INC.
- GRIFOLS BIOLOGICALS, INC. (CONTINUED)
- HAEMONETICS, INC.
- IMMUCOR
- MASSACHUSETTS PUBLIC HEALTH BIOLOGIC LABS
- MEDIMMUNE CORPORATION
- ORTHO-CLINICAL DIAGNOSTICS
- OLYMPUS DIAGNOSTIC SYSTEMS
- TALECRIS BIOTHERAPEUTICS
- Chapter 11 - PATENT ANALYSIS
- TABLE 64 RECENTLY ISSUED PATENTS
- TABLE 65 PATENTS BY COMPANY ASSIGNEE
- TABLE 65 (CONTINUED)
- Chapter 12 - APPENDIX
- PATENTS
- BLOOD TRANSFUSIONS-11 PATENTS
- Blood Transfusions-11 Patents /Continued)
- Blood Transfusions-11 Patents /Continued)
- Blood Transfusions-11 Patents /Continued)
- Blood Transfusions-11 Patents /Continued)
- BLOOD DERIVATIVES-(SEPTEMBER 1986 TO PRESENT)-SEVEN PATENTS
- Blood Derivativesý(Continued)
- Blood Derivativesý(Continued)
- Blood Derivativesý(Continued)
- NUCLEIC ACID AMPLIFICATION (MARCH 2000 TO PRESENT) - 40 PATENTS
- Nucleic Acid Amplificationý(Continued)
- Nucleic Acid Amplificationý(Continued)
- Nucleic Acid Amplificationý(Continued)
- Nucleic Acid Amplificationý(Continued)
- Nucleic Acid Amplificationý(Continued)
- Nucleic Acid Amplificationý(Continued)
- Nucleic Acid Amplificationý(Continued)
- Nucleic Acid Amplificationý(Continued)
- Nucleic Acid Amplificationý(Continued)
- Nucleic Acid Amplificationý(Continued)
- Nucleic Acid Amplificationý(Continued)
- Nucleic Acid Amplificationý(Continued)
- Nucleic Acid Amplificationý(Continued)
- Nucleic Acid Amplificationý(Continued)
- Nucleic Acid Amplificationý(Continued)
- Nucleic Acid Amplificationý(Continued)
- Nucleic Acid Amplificationý(Continued)
- Nucleic Acid Amplificationý(Continued)
- Nucleic Acid Amplificationý(Continued)
- Nucleic Acid Amplificationý(Continued)
- Nucleic Acid Amplificationý(Continued)
- FDA-LICENSED SOURCE PLASMA FACILITIES
- FDA-LICENSED SOURCE PLASMA ý (CONTINUED)
- FDA-LICENSED SOURCE PLASMA ý(CONTINUED)
- FDA-LICENSED SOURCE PLASMA ý(CONTINUED)
- FDA-LICENSED SOURCE PLASMA ý(CONTINUED)
- FDA-LICENSED SOURCE PLASMA ý(CONTINUED)
- FDA-LICENSED SOURCE PLASMA ý(CONTINUED)
- FDA-LICENSED SOURCE PLASMA ý(CONTINUED)
- FDA-LICENSED SOURCE PLASMA ý(CONTINUED)
- FDA-LICENSED SOURCE PLASMA ý(CONTINUED)
- FDA-LICENSED SOURCE PLASMA ý(CONTINUED)
- FDA-LICENSED SOURCE PLASMA ý(CONTINUED)
- FDA-LICENSED SOURCE PLASMA ý(CONTINUED)
- FDA-LICENSED SOURCE PLASMA ý(CONTINUED)
- FDA-LICENSED SOURCE PLASMA ý(CONTINUED)
- FDA-LICENSED SOURCE PLASMA ý(CONTINUED)
- FDA-LICENSED SOURCE PLASMA ý(CONTINUED)
- FDA-LICENSED SOURCE PLASMA ý(CONTINUED)
- GUIDANCE FOR INDUSTRY RECOGNITION AND USE OF A STANDARD FOR THE
UNIFORM LABELING OF BLOOD AND BLOOD COMPONENTS
- INTRODUCTION
- BACKGROUND
- FDA REVIEW AND CONCLUSIONS
- REPORTING REQUIREMENTS FOR LICENSED
- ESTABLISHMENTS
- SUMMARY
|
 |
 |
※この商品は英文にてご提供いたします。 |
|
【 英文市場調査報告書 】
血液産業
The Blood Industry
出版日: 2008/03
|
|
|
|
|
|
※ドル建て価格の商品のお支払いは、銀行レート (TTS: 107.78)
換算による円建てのご請求書にて承ります。
|
商品コード : 63251 |
|
|
|
|
|
|
医薬品
その他のカテゴリ
FAQ